BCL2 and mantle cell lymphoma: Dual targeting BTK and BCL2 with ibrutinib and venetoclax has increased complete response rate compared with ibrutinib monotherapy in MCL patients but it is unlikely that this combination therapy will lead to a long term cure of the disease [3].